Literature DB >> 19540844

Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1.

Dierk Thomas1, Markus Khalil, Markus Alter, Patrick A Schweizer, Christoph A Karle, Anna-Britt Wimmer, Manuela Licka, Hugo A Katus, Michael Koenen, Herbert E Ulmer, Jörg Zehelein.   

Abstract

Hereditary long QT syndrome (LQTS) is a cardiovascular disorder characterized by prolongation of the QT interval on the surface ECG and a high risk for arrhythmia-related sudden death. Mutations in a cardiac voltage-gated potassium channel, KCNQ1, account for the most common form of LQTS, LQTS1. The objective of this study was the characterization of a novel KCNQ1 mutation linked to LQTS. Electrophysiological properties and clinical features were determined and compared to characteristics of a different mutation at the same position. Single-strand conformation polymorphism analysis followed by direct sequencing was performed to screen LQTS genes for mutations. A novel missense mutation in the KCNQ1 gene, KCNQ1 P320H, was identified in the index patient presenting with recurrent syncope and aborted sudden death triggered by physical stress and swimming. Electrophysiological analyses of KCNQ1 P320H and the previously reported KCNQ1 P320A mutation indicate that both channels are non-functional and suppress wild type I(Ks) in a dominant-negative fashion. Based on homology modeling of the KCNQ1 channel pore region, we speculate that the proline residue at position 320 limits flexibility of the outer pore and is required to maintain the functional architecture of the selectivity filter/pore helix arrangement. Our observations on the KCNQ1 P320H mutation are consistent with previous studies indicating that pore mutations in potassium channel alpha-subunits are associated with more severe electrophysiological and clinical phenotypes than mutations in other regions of these proteins. This study emphasizes the significance of mutation screening for diagnosis, risk-assessment, and mutation-site specific management in LQTS patients. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540844     DOI: 10.1016/j.yjmcc.2009.06.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

Review 1.  Diseases caused by mutations in ORAI1 and STIM1.

Authors:  Rodrigo S Lacruz; Stefan Feske
Journal:  Ann N Y Acad Sci       Date:  2015-10-15       Impact factor: 5.691

2.  Recapitulating long-QT syndrome using induced pluripotent stem cell technology.

Authors:  Ralf J Dirschinger; Alexander Goedel; Alessandra Moretti; Karl-Ludwig Laugwitz; Daniel Sinnecker
Journal:  Pediatr Cardiol       Date:  2012-03-13       Impact factor: 1.655

3.  Genomic-based diagnosis of arrhythmia disease in a personalized medicine era.

Authors:  Abdullah Omar; Mi Zhou; Adam Berman; Robert A Sorrentino; Neela Yar; Neal L Weintraub; Il-Man Kim; Wei Lei; Yaoliang Tang
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-12-02

Review 4.  Molecular pathogenesis of long QT syndrome type 1.

Authors:  Jie Wu; Wei-Guang Ding; Minoru Horie
Journal:  J Arrhythm       Date:  2016-01-27

Review 5.  Structures Illuminate Cardiac Ion Channel Functions in Health and in Long QT Syndrome.

Authors:  Kathryn R Brewer; Georg Kuenze; Carlos G Vanoye; Alfred L George; Jens Meiler; Charles R Sanders
Journal:  Front Pharmacol       Date:  2020-05-04       Impact factor: 5.810

6.  Cell death-inducing cytotoxicity in truncated KCNQ4 variants associated with DFNA2 hearing loss.

Authors:  Takashi Kojima; Koichiro Wasano; Satoe Takahashi; Kazuaki Homma
Journal:  Dis Model Mech       Date:  2021-11-26       Impact factor: 5.758

Review 7.  Mutation-Specific Differences in Kv7.1 (KCNQ1) and Kv11.1 (KCNH2) Channel Dysfunction and Long QT Syndrome Phenotypes.

Authors:  Peter M Kekenes-Huskey; Don E Burgess; Bin Sun; Daniel C Bartos; Ezekiel R Rozmus; Corey L Anderson; Craig T January; Lee L Eckhardt; Brian P Delisle
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.